Abstract
Tuberculosis (TB) with central nervous system (CNS) manifestation is a form of TB with a high mortality and morbidity. Tuberculous meningitis (TM) is the most common form of CNS-TB. Although diagnosis of CNS-TB can be challenging, early treatment of CNS-TB is related to a better outcome. If CNS-TB is suspected, even though the clinical picture is not specific, it should be immediately treated.
For the treatment of CNS-TB, knowledge of the penetration across the blood-brain barrier of the various antituberculosis agents used in TB treatment is important. These will be described here in order to serve as a guide in choosing a treatment for CNS-TB. Corticosteroids have an evidence-based value in the treatment of TM and so are recommended. As for thalidomide use in CNS-TB, sound evidence is still lacking. We will also include a description of the adverse neurotoxic effects of the various other agents including their psychiatric, ototoxic and ophthalmic adverse effects.
Keywords: Tuberculosis, central nervous system, tuberculous meningitis, antituberculosis agents, blood-brain barrier, corticosteroids, thalidomide, adverse neurotoxic effects, HIV infection, enzyme-linked immunospot assay (ELISpot assay)
Current Pharmaceutical Design
Title: Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Volume: 17 Issue: 27
Author(s): J. J. van der Harst and G. J. Luijckx
Affiliation:
Keywords: Tuberculosis, central nervous system, tuberculous meningitis, antituberculosis agents, blood-brain barrier, corticosteroids, thalidomide, adverse neurotoxic effects, HIV infection, enzyme-linked immunospot assay (ELISpot assay)
Abstract: Tuberculosis (TB) with central nervous system (CNS) manifestation is a form of TB with a high mortality and morbidity. Tuberculous meningitis (TM) is the most common form of CNS-TB. Although diagnosis of CNS-TB can be challenging, early treatment of CNS-TB is related to a better outcome. If CNS-TB is suspected, even though the clinical picture is not specific, it should be immediately treated.
For the treatment of CNS-TB, knowledge of the penetration across the blood-brain barrier of the various antituberculosis agents used in TB treatment is important. These will be described here in order to serve as a guide in choosing a treatment for CNS-TB. Corticosteroids have an evidence-based value in the treatment of TM and so are recommended. As for thalidomide use in CNS-TB, sound evidence is still lacking. We will also include a description of the adverse neurotoxic effects of the various other agents including their psychiatric, ototoxic and ophthalmic adverse effects.
Export Options
About this article
Cite this article as:
J. van der Harst J. and J. Luijckx G., Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment, Current Pharmaceutical Design 2011; 17(27) . https://dx.doi.org/10.2174/138161211797470237
DOI https://dx.doi.org/10.2174/138161211797470237 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability
CNS & Neurological Disorders - Drug Targets Clinical and Electroencephalographic Assessment of Cefepime During Treatment of Nosocomial Infections in Neurological Patients
Central Nervous System Agents in Medicinal Chemistry The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease
Current Topics in Medicinal Chemistry Highlights in the Development of New Antiviral Agents
Mini-Reviews in Medicinal Chemistry Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
CNS & Neurological Disorders - Drug Targets Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry Inflammatory Cytokines in Acute Ischemic Stroke
Current Pharmaceutical Design Cerebral Collateral Circulation in Carotid Artery Disease
Current Cardiology Reviews CSF Ubiquitin As a Specific Biomarker in Alzheimer's Disease
Current Alzheimer Research Synthesis of Pyrophosphate-Containing Compounds that Stimulate VγVδ2 T Cells: Application to Cancer Immunotherapy
Medicinal Chemistry Nitric Oxide, Epileptic Seizures, and Action of Antiepileptic Drugs
CNS & Neurological Disorders - Drug Targets Diagnosis of Systemic Lupus Erythematosus in an Unusual Presentation: What a Primary Care Physician Should Know
Current Rheumatology Reviews Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology Long-Term CD4 Cell Count Recovery among Thai Naive HIV-Infected Patients Initiating HAART at Low CD4 Cell Count
Current HIV Research Brucellosis Serostatus Among Pregnant Women with Spontaneous Abortion and Stillbirth
Current Women`s Health Reviews Functional Polymeric Nano/Microparticles for Surface Adsorption and Delivery of Protein and DNA Vaccines
Current Drug Delivery Evaluation of Audiometric Thresholds and Speech Perception Sentence Test in Adults and Elderly After Cochlear Implantation
Current Aging Science Immunoinformatic Approach for the Identification of Potential Epitopes Against <i>Stenotrophomonas maltophilia</i>: A Global Opportunistic Pathogen
Letters in Drug Design & Discovery Drug Targeting to the Brain - A Review
Current Nanoscience Drug Delivery Systems for Brain Tumor Therapy
Current Pharmaceutical Design